CRISPR technology is transforming modern medicine by enabling precise DNA editing to treat genetic disorders, including sickle cell anemia and beta-thalassemia, experts say.

Deferiprone market was valued at US$ 39.89 million in 2024 and is projected to hit the market valuation of US$ 55.22 million by 2033 at a CAGR of 3.68% during the forecast period 2025–2033.

Nagpur: The Nagpur Municipal Corporation (NMC) recently undertook a comprehensive survey to collect data on persons with disabilities across the city..

CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...

Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

In the darkest hour of the pandemic, when the world was gripped with fear and confusion, a leader emerged not merely with policies and protocols but with symbolism that ignited unity. The call to ...

In a major advancement for global thalassemia care, the results of a landmark global phase 3 clinical trial of mitapivat in ...

The Maharashtra government is set to implement mandatory pre-marital thalassemia testing as part of a campaign to eradicate the genetic disorder. Minister Meghana Bordikar announces new rules amid ...

Thalassemia is a category of inherited blood disorders, becoming a primary health threat due to its increased prevalence worldwide. Through examination and testing of Thalassemia is widely accessible ...

Maharashtra is planning to make thalassemia testing mandatory before marriage, as part of its campaign to eradicate the genetic blood disorder.

While responding to a question raised by MLA Vikas Thakre during Question Hour, Maharashtra Minister said the state accounts ...

Maharashtra is set to mandate pre-marital thalassemia testing to combat the genetic blood disorder affecting thousands. The ...